AstraZeneca : Saphnelo is a first-in-class type I interferon

AstraZeneca : Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus (Form 6-K)

AstraZeneca : Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus (Form 6-K)

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Japan , Tokyo , United States , Kobe , Hyogo , America , Japanese , British , Tsutomu Takeuchi , Yoshiya Tanaka , Astrazeneca Saphnelo , Adrian Kemp , Japan College Of Rheumatology , Medarex Inc , University Of Occupational , Environmental Health , American College Of Rheumatology , Prevention National Lupus Registries , Nasdaq , Company On Twitter Astrazeneca , Astrazeneca , Lupus Foundation Of America , Centers For Disease , Analysis Of The Centers For Disease , First Department Of Internal Medicine , Professor Of Keio University , National Registry Of Designated Intractable Diseases , Japanese Ministry Of Health , Investor Relations Team , Japan Intractable Diseases Information Center , Japanese Ministry , First Department , Internal Medicine , Emeritus Professor , Keio University , Executive Vice President , Intractable Disease , New England Journal , Lancet Rheumatology , Japan College , Bristol Myers Squibb , Uncontrolled Lupus , Interferon Pathway , Based Composite Lupus Assessment , Rare Diseases , Active Systemic Lupus , Receptor Monoclonal Antibody , Severe Systemic Lupus , Disease Control , Systemic Lupus Erythematosus , Estimates From , Prevention National Lupus , Designated Intractable Diseases , Present Status , Neurol Med Chir , Intractable Diseases Information , Annual General Assembly , Scientific Meeting , Lupus Foundation , Term Safety , Adult Patients With Systemic Lupus Erythematosus , Typei Interferons , Basic Concepts , Clinical Relevance , Immune Mediated Inflammatory ,